Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. Our first commercial product, Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor anticoagulant, is approved in the United States. We are also advancing the clinical development of two other compounds, including AndexXa® (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor, and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Our partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. We have approximately 170 employees.
- Bevyxxa® (betrixaban) was approved by the FDA on June 23, 2017. Learn More.
- AndexXa® (andexanet alfa) is being developed as a reversal agent for patients anticoagulated with an oral or injectable Factor Xa inhibitor who experience a serious uncontrolled bleeding event or who require urgent or emergent surgery. Designated a Breakthrough Therapy by the U.S. Food and Drug Administration. Currently being studied in ANNEXA-4, a Phase 3b/4 single-arm, open-label confirmatory study in patients receiving apixaban, rivaroxaban, edoxaban or enoxaparin (a low molecular weight heparin and indirect Factor Xa inhibitor) who present with an acute major bleed. Portola has commercial rights to andexanet alfa outside of Japan. Learn more.
- Cerdulatinib – Oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor that uniquely inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies – the B-cell receptor pathway via Syk and key cytokine receptors via JAK Being developed to treat patients with hematologic cancers, specifically those who have relapsed or who have not responded to prior therapies. Portola has worldwide rights to develop and commercialize cerdulatinib. Learn more.